Evaluation of genotype® mtbdrplus for the detection of multi-drug-resistant mycobacterium tuberculosis strains

Kekkaku

Volumn 86, Issue 7, 2011, Pages 697-702

  Chikamatsu, Kinuyo ^a   Mizuno, Kazue ^a   Aono, Akio ^a   Yamada, Hiroyuki ^a   Sugamoto, Tetsuhiro ^a   Nishiyama, Hiroyuki ^b   Mitarai, Satoshi ^a  

^a JPN Anti Tuberculosis Association   (Japan)

^b FUKUJUJI HOSPITAL   (Japan)

Author keywords

Inha; Isoniazid; Katg; Line probe assay; Multi drug resistant mycobacterium tuberculosis; Rifampicin; Rpob

Indexed keywords

BACTERIAL DNA; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; DRUG EFFECT; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION; NUCLEIC ACID HYBRIDIZATION;

ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; DNA, BACTERIAL; GENOTYPE; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; NUCLEIC ACID HYBRIDIZATION; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 80053522007     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. World Health Organization: Anti-tuberculosis drug resistance in the world. Report No. 4. WHO/HTM/TB/2008.394. Geneva, World Health Organization, 2008.
2. Hillemann D, Rusch-Gerdes S, Richter E: Evaluation of GenoType MTBDR ws assay for rifampicin and strains and clinical specimens. J Clin Microbiol. 2007; 45 : 2635- 2640.
3. Williams DL, Waguespack C, Eisenach K, et al.: Character ization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother. 1994; 38 : 2380-2386.
4. Morlock GP, Metchock B, Sikes D, et al.: katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2003; 47:3799-3805.
5. Causse M, Ruiz P, Gutierrez B, et al.: M. Evaluation of new GenoType® MTBDRp/wj for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2008; 12 : 1456-1460.
6. Brossier F, Veziris N, Jarlier V, et al.: Performance of MTBDRplus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. Int J Tuberc Lung Dis. 2009; 13 : 260-265.
7. Huang W-L, Chen H-Y, Kuo Y-M, et al.: Performance assessment of the GenoType MTBDR plus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol. 2009; 47 : 2520-2524.
8. Telenti A, Imboden P, Marchesi F, et al.: Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993; 341 : 647-650.
9. Matsiota-Bernard P, Vrioni G, Marinis E: Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Greece. J Clin Microbiol. 1998; 36 : 20-23.
10. Park H, Song EJ, Song ES, et al.: Comparison of a conventional antimicrobial susceptibility assay to an oligonucleotide chip system for detection of drug resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2006; 44 : 1619-1624.
11. Abe C, Kobayashi I, Mitarai S, et al.: Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance isoniazid in Japan. J Clin Microbiol. 2008; 46 : 2263-2268.
12. Ando Hf, Kondo Y, Suctake T, et al. Identification of katG mutation associated with high-level isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2010; 54: 1793-1799.
13. Tuberculosis Research Committee (Ryoken): Drug-resistant Mycobacterium tuberculosis in Japan: A nationwide survey, 2002. Int J Tuberc Lung Dis. 2007; 11 : 1129-1135.